UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Operating revenue:
Personalized oncology solutions	$ 347,000	$ 416,000	$ 1,354,000	$ 1,387,000
Translational oncology solutions	3,218,000	2,136,000	10,337,000	6,958,000
Total operating revenue	3,565,000	2,552,000	11,691,000	8,345,000
Costs and operating expenses:
Cost of personalized oncology solutions	320,000	479,000	1,167,000	1,661,000
Cost of translational oncology solutions	2,086,000	1,627,000	5,965,000	4,683,000
Research and development	998,000	999,000	3,217,000	3,018,000
Sales and marketing	726,000	779,000	2,369,000	2,688,000
General and administrative	836,000	1,041,000	3,393,000	4,062,000
Total costs and operating expenses	4,966,000	4,925,000	16,111,000	16,112,000
Loss from operations	(1,401,000)	(2,373,000)	(4,420,000)	(7,767,000)
Other (expense):
Other (expense)	(8,000)	(8,000)	(33,000)	(29,000)
Total other (expense)	(8,000)	(8,000)	(33,000)	(29,000)
Loss before provision for income taxes	(1,409,000)	(2,381,000)	(4,453,000)	(7,796,000)
Provision for income taxes	0	31,000	7,000	76,000
Net loss	$ (1,408,904)	$ (2,412,381)	$ (4,459,773)	$ (7,872,115)
Net loss per common share outstanding
Net loss per common share outstanding, basic and diluted (in dollars per share)	$ (0.13)	$ (0.28)	$ (0.44)	$ (0.90)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic and diluted (in shares)	10,967,738	8,702,237	10,130,460	8,702,237